MAPT and Alzheimer disease: One drawback of fluid biomarkers is the inability to follow brain-specific changes and the spatial distribution of the pathology, which make disease staging more challenging compared to brain imaging, thus suggesting that noninvasive tau PET imaging is still an irreplaceable tool for estimating density and distribution of tau pathology in AD.